March 31,

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 10-Q


[X]      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2007 or

[  ]      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________to _________

Commission File Number 0-21229

Stericycle, Inc.
(Exact name of registrant as specified in its charter)


 Delaware

36-3640402

 (State or other jurisdiction of incorporation or organization) 

(IRS Employer Identification Number)


28161 North Keith Drive
Lake Forest, Illinois    60045
(Address of principal executive offices including zip code)

(847) 367-5910
(Registrant's telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES [X] NO [  ]

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See the definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer [X] Accelerated filer [  ]  Non-accelerated filer [  ]

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2).  YES [  ]  NO [X ]

As of November 1, 2007 there were 86,907,305 shares of the Registrant's Common Stock outstanding.




[form10q001.jpg]


Stericycle, Inc.

Table of Contents


 

 

 

Page No.

PART I.  Financial Information

 

 

 

 

 

Item 1.  Financial Statements

 

 

Condensed Consolidated Balance Sheets as of

 

 

 

September 30, 2007 (Unaudited) and December 31, 2006 (Audited)

1

 

 

 

 

 

Condensed Consolidated Statements of Income

 

 

 

for the three and nine months ended September 30, 2007 and 2006 (Unaudited)

2

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows

 

 

 

for the nine months ended September 30, 2007 and 2006 (Unaudited)

3

 

 

 

 

 

Notes to Condensed Consolidated Financial Statements (Unaudited)

4

 

 

 

 

Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations

12

 

 

 

 

Item 3.  Qualitative and Quantitative Disclosures about Market Risk

18

 

 

 

 

Item 4.  Controls and Procedures

18

 

 

 

 

PART II.  Other Information

 

 

 

 

 

Item 1.  Legal Proceedings

20

 

 

 

 

Item 2.  Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities

20

 

 

 

 

Item 6.  Exhibits

21

 

 

 

 

Signature

21

 

 

 

 

Certifications

22











PART I. – FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

STERICYCLE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS


In thousands, except share and per share data

 

 

September 30,

 

 

December 31,

 

 

2007

 

 

2006

 

 

(Unaudited)

 

 

(Audited)

 ASSETS

 

 

 

 

 

Current Assets:

 

 

 

 

 

     Cash and cash equivalents

$

7,703

 

$

13,492

     Short-term investments

 

812

 

 

2,548

     Accounts receivable, less allowance for doubtful

         accounts of $5,985 in 2007 and $5,411 in 2006

 

154,763

 

 

130,354

     Deferred income taxes

 

14,431

 

 

16,072

     Assets of disposal group held for sale

 

--

 

 

33,674

     Other current assets

 

26,514

 

 

22,462

         Total Current Assets

 

204,223

 

 

218,602

Property, Plant and Equipment, net

 

185,327

 

 

156,953

Other Assets:

 

 

 

 

 

     Goodwill

 

920,848

 

 

813,973

     Intangible assets, less accumulated amortization of

         $14,068 in 2007 and $11,454 in 2006

 

143,664

 

 

115,879

     Notes receivable

 

12,901

 

 

14,546

     Other

 

7,334

 

 

7,953

         Total Other Assets

 

1,084,747

 

 

952,351

Total Assets

$

1,474,297

 

$

1,327,906

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

Current liabilities:

 

 

 

 

 

     Current portion of long-term debt

$

16,440

 

$

22,681

     Accounts payable

 

35,597

 

 

25,033

     Accrued liabilities

 

75,064

 

 

75,434

     Deferred revenue

 

13,507

 

 

11,662

     Liabilities of disposal group held for sale

 

--

 

 

7,221

         Total Current Liabilities

 

140,608

 

 

142,031

Long-term debt, net of current portion

 

545,146

 

 

443,115

Deferred income taxes

 

119,009

 

 

105,521

Other liabilities

 

13,468

 

 

12,158

Common Shareholders' Equity:

 

 

 

 

 

  

Common stock (par value $.01 per share, 120,000,000

     

shares authorized, 86,971,032 issued and outstanding

    

 in 2007, 88,503,930 issued and outstanding in 2006)

 

870

 

 

886

  

Additional paid-in capital

 

180,042

 

 

252,125

 

Accumulated other comprehensive income

 

14,033

 

 

5,229

  

Retained earnings

 

461,121

 

 

366,841

         Total Shareholders' Equity

 

656,066

 

 

625,081

Total Liabilities and Shareholders' Equity

$

1,474,297

 

$

1,327,906


The accompanying notes are an integral part of these financial statements.



1




STERICYCLE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)


In thousands, except share and per share data

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2007

 

 

2006

 

 

2007

 

 

2006

Revenues

$

237,323

 

$

203,267

 

$

681,217

 

$

580,940

 

 

 

 

 

 

 

 

 

 

 

 

Costs and Expenses:

 

 

 

 

 

 

 

 

 

 

 

     Cost of revenues

 

124,799

 

 

107,700

 

 

358,995

 

 

309,426

     Selling, general and

         administrative expenses

 

42,496

 

 

34,912

 

 

121,391

 

 

101,549

     Depreciation and amortization

 

7,808

 

 

7,101

 

 

22,654

 

 

20,109

     Gain on sale of business

 

     --

 

 

--

 

 

(1,898)

 

 

--

     Impairment of intangible assets

 

 --

 

 

 --

 

 

228

 

 

 --

     Impairment of fixed assets

 

 --

 

 

 --

 

 

1,261

 

 

300

     Acquisition integration expenses

 

360

 

 

519

 

 

1,279

 

 

1,814

         Total Costs and Expenses

 

175,463

 

 

150,232

 

 

503,910

 

 

433,198

Income from Operations

 

61,860

 

 

53,035

 

 

177,307

 

 

147,742

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

     Interest income

 

307

 

 

490

 

 

1,245

 

 

997

     Interest expense

 

(8,864)

 

 

(7,810)

 

 

(24,840)

 

 

(20,969)

     Insurance proceeds

 

--

 

 

--

 

 

500

 

 

--

     Other expense, net

 

(247)

 

 

(580)

 

 

(1,030)

 

 

(2,810)

         Total Other Expense

 

(8,804)

 

 

(7,900)

 

 

(24,125)

 

 

(22,782)

 

 

 

 

 

 

 

 

 

 

 

 

Income Before Income Taxes

 

53,056

 

 

45,135

 

 

153,182

 

 

124,960

 

 

 

 

 

 

 

 

 

 

 

 

Income Tax Expense

 

20,161

 

 

17,603

 

 

58,902

 

 

48,735

 

 

 

 

 

 

 

 

 

 

 

 

Net Income

$

32,895

 

$

27,532

 

$

94,280

 

$

76,225

 

 

 

 

 

 

 

 

 

 

 

 

Earnings Per Common Share:

 

 

 

 

 

 

 

 

 

 

 

     Basic

$

0.38

 

$

0.31

 

$

1.07

 

$

0.86

     Diluted

$

0.37

 

$

0.30

 

$

1.05

 

$

0.84

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Number of

     Common Shares Outstanding:

 

 

 

 

 

 

 

 

 

 

 

     Basic

 

87,299,448

 

 

88,512,004

 

 

87,735,838

 

 

88,383,182

     Diluted

 

89,794,892

 

 

90,495,268

 

 

90,068,563

 

 

90,485,544


The accompanying notes are an integral part of these financial statements.



2




STERICYCLE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


In thousands

 

 

Nine Months Ended September 30,

 

 

2007

 

 

2006

OPERATING ACTIVITIES:

 

 

 

 

 

Net income

$

94,280

 

$

76,225

Adjustments to reconcile net income to net cash provided by

   operating activities:

 

 

 

 

 

     Gain on sale of assets

 

(1,898)

 

 

--

     Impairment of fixed assets

 

1,261

 

 

300

     Impairment of permit intangible

 

228

 

 

 --

     Write down of investment in securities

 

 --

 

 

1,000

     Stock compensation expense

 

7,855

 

 

7,927

     Excess tax benefit of disqualifying dispositions of stock

         options and exercise of non-qualified stock options

 

(3,414)

 

 

(7,783)

     Depreciation

 

19,975

 

 

17,636

     Amortization

 

2,679

 

 

2,473

     Deferred income taxes

 

11,958

 

 

7,814

Changes in operating assets and liabilities, net of effect of

   acquisitions and divestitures:

 

 

 

 

 

     Accounts receivable

 

(13,931)

 

 

(18,131)

     Accounts payable

 

6,044

 

 

(6,466)

     Accrued liabilities

 

(445)

 

 

34,430

     Deferred revenue

 

1,706

 

 

1,015

     Other assets

 

1,845

 

 

(1,723)

Net cash provided by operating activities

 

128,143

 

 

114,717

 

 

 

 

 

 

INVESTING ACTIVITIES:

 

 

 

 

 

     Payments for acquisitions and international investments,

         net of cash acquired

 

(78,966)

 

 

(142,922)

     Proceeds from maturity/(purchase) of short-term investments

 

1,763

 

 

(2,901)

     Proceeds from sale of assets

 

26,453

 

 

--

     Proceeds from sale of property and equipment

 

--

 

 

601

     Capital expenditures

 

(37,602)

 

 

(25,556)

Net cash used in investing activities

 

(88,352)

 

 

(170,778)

 

 

 

 

 

 

FINANCING ACTIVITIES:

 

 

 

 

 

     Proceeds from issuance of note payable

 

--

 

 

5,953

     Repayment of long-term debt

 

(32,374)

 

 

(13,936)

     Net borrowings on senior credit facility

 

68,623

 

 

69,592

     Principal payments on capital lease obligations

 

(49)

 

 

(669)

     Payments of deferred financing costs

 

--

 

 

(453)

     Purchase/ cancellation of treasury stock

 

(95,174)

 

 

(26,060)

     Proceeds from other issuance of common stock

 

11,441

 

 

13,122

     Excess tax benefit of stock options exercised

 

3,414

 

 

7,783

Net cash (used in)/ provided by financing activities

 

(44,119)

 

 

55,332

Effect of exchange rate changes on cash

 

(1,461)

 

 

(2,916)

Net decrease in cash and cash equivalents

 

(5,789)

 

 

(3,645)

Cash and cash equivalents at beginning of period

 

13,492

 

 

7,825

Cash and cash equivalents at end of period

$

7,703

 

$

4,180

 

 

 

 

 

 

NON-CASH ACTIVITIES:

 

 

 

 

 

Net issuance of notes payable for certain acquisitions

$

54,108

 

$

27,957

Net issuance of common stock for certain acquisitions

 

365

 

 

750


The accompanying notes are an integral part of these financial statements.



3




STERICYCLE, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)


Unless the context requires otherwise, “we”, “us” or “our” refers to Stericycle, Inc. and its subsidiaries on a consolidated basis.



NOTE 1 – BASIS OF PRESENTATION


The accompanying condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations; but the Company believes the disclosures in the accompanying condensed consolidated financial statements are adequate to make the information presented not misleading.  In our opinion, all adjustments necessary for a fair presentation for the periods presented have been reflected and are of a normal recurring nature.  These condensed consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and notes thereto for the year ended December 31, 2006, as filed with our Annual Report on Form 10-K for the year ended December 31, 2006.  The results of operations for the nine months ended September 30, 2007 are not necessarily indicative of the results that may be achieved for the entire year ending December 31, 2007.  As more fully described in Note 5, share and per share data have been adjusted to reflect a 2-for-1 stock split effective May 31, 2007.



NOTE 2 – ACQUISITIONS AND DIVESTITURE


During the quarter ended March 31, 2007, we completed five acquisitions, of which three were domestic medical waste businesses, one was a domestic manufacturer of containers that we use in our mail-back program for medical waste, and one was a medical waste business in Latin America.  We acquired all of the stock of one domestic business, and we acquired selected assets of the other four businesses.


During the quarter ended June 30, 2007, we completed six acquisitions, of which two were domestic medical waste businesses, three were medical waste businesses in Latin America, and one was a medical waste business in Europe.  We acquired all of the stock of the four international businesses, and we acquired selected assets of the two domestic businesses.


During the quarter ended September 30, 2007, we completed two domestic acquisitions of medical waste businesses.  We acquired all of the stock of one domestic business, and we acquired selected assets of the other domestic business.


The aggregate net purchase price of all our acquisitions, including adjustments for purchase accounting, during the nine months ended September 30, 2007 was



4




approximately $133.4 million, of which $78.9 million was paid in cash, $54.1 million was paid by the issuance of promissory notes and $0.4 million was paid by the issuance of shares of our common stock.  These acquisitions were not significant to our operations, either individually or in the aggregate.  For financial reporting purposes these acquisition transactions were accounted for using the purchase method of accounting.  The purchase prices of these acquisitions, in excess of acquired tangible assets, have been primarily allocated to goodwill and are preliminary pending completion of certain intangible asset valuations.  For financial reporting purposes these acquisition transactions were accounted for using the purchase method of accounting.  The results of operations of these acquired businesses have been included in the consolidated statements of income from the dates of acquisition.  These acquisitions resulted in recognition of goodwill in our financial statements reflecting the complementary strategic fit that the acquired businesses brought to us.


In February 2007, we sold three incinerators and associated customer contracts in the United Kingdom to comply with a remedy accepted by United Kingdom Competition Commission, as we reported in our Form 10-K for 2006.  The sales price was $26.5 million and resulted in a gain of approximately $1.9 million.  The selected assets and related liabilities are presented on our balance sheet at December 31, 2006 as “Assets of disposal group held for sale” and “Liabilities of disposal group held for sale”.



NOTE 3 – INCOME TAXES


In September 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109" ("FIN 48").  This interpretation clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 109, “Accounting for Income Taxes”.  This Interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return.  This interpretation also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.  We adopted the provisions of FIN 48 on January 1, 2007.  The adoption of FIN 48 did not have a material impact on our consolidated financial statements.


We and our subsidiaries file U.S. federal income tax returns and income tax returns in various states and foreign jurisdictions.  With a few exceptions, we are no longer subject to U.S. federal, state, local, or non-U.S. income tax examinations by tax authorities for years before 2001.  In the third quarter of 2006 the Internal Revenue Service (“IRS”) began an examination of the Company's U.S. income tax return for 2004.  This examination was settled in the second quarter of 2007, and we paid an immaterial amount during the third quarter of 2007 for additional tax and interest with respect to adjustments to our deduction for state income tax expense and currency losses.  Tax years 2005 and 2006 remain open and subject to examination by the IRS, and our subsidiaries in foreign countries have tax years open ranging from 2002 through 2006.




5




The total amount of income tax contingency reserve as of January 1, 2007 is $4.4 million, which includes immaterial amounts of interest and penalties and is reflected as a liability on the balance sheet.  The amount of income tax contingency reserve that, if recognized, would affect the effective tax rate is approximately $4.4 million.  At September 30, 2007, the balances have not materially changed nor do we expect a significant increase or decrease to these balances over the next twelve months.  We recognize interest and penalties accrued related to income tax reserves in income tax expense.  This method of accounting is consistent with prior years.  



NOTE 4 – STOCK BASED COMPENSATION


At September 30, 2007 we had stock options outstanding under the following plans:

(i)

the 2005 Incentive Stock Plan, which our stockholders approved in April 2005;

(ii)

the 2000 Nonstatutory Stock Option Plan, which our Board of Directors adopted in February 2000;

(iii)

the 1997 Stock Option Plan, which expired in January 2007;

(iv)

the Directors Stock Option Plan, which expired in May 2006;

(v)

the 1995 Incentive Compensation Plan, which expired in July 2005;

(vi)

and our Employee Stock Purchase Plan, which our stockholders approved in May 2001.


The following table sets forth the expense related to stock compensation:


In thousands

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2007

 

 

2006

 

 

2007

 

 

2006

Stock options

$

2,669

 

$

2,578

 

$

7,546

 

$

7,704

Employee stock purchase program

 

112

 

 

75

 

 

309

 

 

223

Total pre-tax expense

$

2,781

 

$

2,653

 

$

7,855

 

$

7,927


The following table sets forth the tax benefits related to stock compensation:


In thousands

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2007

 

 

2006

 

 

2007

 

 

2006

Tax benefit recognized in income

   statement

$

1,025

 

$

959

 

$

3,413

 

$

2,854

Excess tax benefit realized

 

970

 

 

4,642

 

 

3,414

 

 

7,783


The Black-Scholes option-pricing model is used in determining the fair value of each option grant using the assumptions noted in the table below.  The expected term of options granted is based on historical experience and represents the period of time that awards granted are expected to be outstanding.  Expected volatility is based upon historical volatility of the company’s stock.  The expected dividend yield is zero.  The



6




risk-free interest rate for 2007 is based on the U.S. Treasury five-year yield rate that equals the expected term of the award.  The risk free interest rate for 2006 is based upon the average of the U.S. Treasury three and five year rates, which equal the expected term of the award.


The significant weighted average assumptions relating to the valuation of the stock options granted during the three and nine months ended September 30, 2007 and 2006, were as follows:


 

Three Months Ended

 

Nine Months Ended

 

September 30,

 

September 30,

 

2007

 

 

2006

 

2007

 

 

2006

Expected term (in years)

5.0

 

 

4.5

 

5.0

 

 

4.4

Expected volatility

26.10%

 

 

28.33%

 

27.07%

 

 

28.94%

Expected dividend yield

0.00%

 

 

0.00%

 

0.00%

 

 

0.00%

Risk free interest rate

4.29%

 

 

4.67%

 

4.53%

 

 

4.85%


The weighted average grant date fair value of the stock options granted during the three and nine months ended September 30, 2007 and 2006, was $13.04 and $9.16, and $11.38 and $8.81, respectively.


Stock option activity for the nine months ended September 30, 2007, was as follows:


 

Number of options

 

 

Weighted average exercise price per share

 

Weighted average remaining contractual life

 

 

Aggregate intrinsic value

 

 

 

 

 

 

(in years)

 

 

 

Outstanding at December 31, 2006

7,037,310

 

$

20.96

 

 

 

 

 

Granted

1,450,903

 

 

40.01

 

 

 

 

 

Exercised

(641,783)

 

 

16.69

 

 

 

 

 

Cancelled or expired

(204,508)

 

 

29.05

 

 

 

 

 

Outstanding at September 30, 2007

7,641,922

 

$

24.72

 

6.92

 

$

247,906,517

Exercisable at September 30, 2007

3,728,483

 

$

17.68

 

5.43

 

$

147,191,755

Vested and expected to vest in the future

    at September 30, 2007

6,840,431

 

$

23.72

 

0.73

 

$

228,737,679


The total intrinsic value of options exercised for the three and nine months ended September 30, 2007 and 2006 was $4.6 million and $16.3 million, and $17.4 million and $30.7 million, respectively.  Intrinsic value is measured using the fair market value at the date of the exercise (for options exercised) or at September 30, 2007 (for outstanding options), less the applicable exercise price.


As of September 30, 2007, there was $14.9 million of total unrecognized compensation expense, related to non-vested compensation expense, which is expected to be recognized over a weighted-average period of 1.85 years.





7




NOTE 5 – COMMON STOCK


Share and per share data have been adjusted to reflect a 2-for-1 stock split effective May 31, 2007.


During the quarter ended March 31, 2007, we repurchased on the open market, and subsequently cancelled, 1,179,572 shares of common stock.  The weighted average repurchase price was $39.06 per share.


During the quarter ended June 30, 2007 our shareholders approved the increase in our authorized shares of common stock from 80,000,000 shares to 120,000,000 shares.  In addition, the Board of Directors authorized a 2-for-1 stock split.  The stock split was in the form of a stock dividend of one share payable on May 31, 2007 in respect of each share of common stock outstanding on the record date of May 17, 2007, as reported in our current report on Form 8-K filed on May 17, 2007.  Historic share and per share amounts have been adjusted to reflect the stock split.  During the quarter ended June 30, 2007, we repurchased, and subsequently cancelled, 291,566 shares of common stock.  The weighted average repurchase price was $43.18 per share.


During the quarter ended September 30, 2007, we repurchased on the open market, and subsequently cancelled, 757,219 shares of common stock.  The weighted average repurchase price was $48.22 per share.



NOTE 6 – NET INCOME PER COMMON SHARE


The following table sets forth the computation of basic and diluted net income per share:


In thousands, except share and per share data

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2007

 

 

2006

 

 

2007

 

 

2006

Numerator:

 

 

 

 

 

 

 

 

 

 

 

Numerator for basic earnings per share

 

 

 

 

 

 

 

 

 

 

 

     Net income

$

32,895

 

$

27,532

 

$

94,280

 

$

76,225

Denominator:

 

 

 

 

 

 

 

 

 

 

 

Denominator for basic earnings per

     share-weighted average shares

 

87,299,448

 

 

88,512,004

 

 

87,735,838

 

 

88,383,182

Effect of diluted securities:

 

 

 

 

 

 

 

 

 

 

 

Employee stock options

 

2,488,915

 

 

1,982,696

 

 

2,328,004

 

 

2,101,836

Warrants

 

6,529

 

 

568

 

 

4,721

 

 

526

Dilutive potential shares

 

2,495,444

 

 

1,983,264

 

 

2,332,725

 

 

2,102,362

Denominator for diluted earnings per

     share-adjusted weighted average

     shares and after assumed exercises

 

89,794,892

 

 

90,495,268

 

 

90,068,563

 

 

90,485,544

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share – Basic

$

0.38

 

$

0.31

 

$

1.07

 

$

0.86

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share – Diluted

$

0.37

 

$

0.30

 

$

1.05

 

$

0.84



8








NOTE 7 – COMPREHENSIVE INCOME


The components of total comprehensive income are net income, the change in cumulative currency translation adjustments and gains and losses on derivative instruments qualifying as cash flow hedges.  The following table sets forth the components of total comprehensive income for the three and nine months ended September 30, 2007 and 2006:


In thousands

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2007

 

 

2006

 

 

2007

 

 

2006

Net income

$

32,895

 

$

27,532

 

$

94,280

 

$

76,225

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

     Currency translation adjustments

 

4,094

 

 

1,174

 

 

8,660

 

 

3,762

     Net gain on derivative instruments

 

596

 

 

226

 

 

144

 

 

131

         Other comprehensive income

 

4,690

 

 

1,400

 

 

8,804

 

 

3,893

 

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive income

$

37,585

 

$

28,932

 

$

103,084

 

$

80,118



NOTE 8 – GUARANTEE


We have guaranteed a loan to JPMorganChase Bank N.A. on behalf of Shiraishi-Sogyo Co. Ltd (“Shiraishi”).  Shiraishi is a customer in Japan that is expanding their medical waste management business and has a six month loan with a current balance of $4.2 million with JPMorganChase Bank N.A. that expires in November 2007.  The loan with JPMorganChase and our associated guarantee will be extended until May 2008.



NOTE 9 – GOODWILL


We have two geographical reporting segments, United States and Foreign Countries, both of which have goodwill.  The changes in the carrying amount of goodwill, net of amortization, for the nine months ended September 30, 2007 were as follows:


In thousands

 

 

United States

 

 

Foreign Countries

 

 

Total

Balance as of January 1, 2007

$

647,524

 

$

166,449

 

$

813,973

Changes due to currency fluctuation

 

--

 

 

6,009

 

 

6,009

Allocated intangibles

 

483

 

 

(8,502)

 

 

(8,019)

Changes in goodwill on 2006 acquisitions

 

122

 

 

2,462

 

 

2,584

Goodwill on 2007 acquisitions

 

95,589

 

 

10,712

 

 

106,301

Balance as of September 30, 2007

$

743,718

 

$

177,130

 

$

920,848




9




During the quarter ended June 30, 2007 we performed our annual goodwill impairment evaluation for our three operating units, Domestic Regulated Medical Waste, Domestic Regulated Returns Management, and Foreign Countries, and determined that none of our recorded goodwill was impaired.  We complete our annual impairment analysis of our indefinite lived intangibles (facility permits) during the quarter ended December 31 of each year.



NOTE 10 – LEGAL PROCEEDINGS


We operate in a highly regulated industry and must deal with regulatory inquiries or investigations from time to time that may be instituted for a variety of reasons.  We are also involved in a variety of civil litigation from time to time.


In Australia, we are currently in arbitration proceedings with SteriCorp Limited (“SteriCorp”) over the performance of equipment sold to them. In September 2007 we received interim findings from the arbitrator.  The interim award found in our favor on our claim against SteriCorp for payments due under certain convertible notes and found in SteriCorp’s favor on its claims that we failed to supply SteriCorp with equipment conforming to specifications under an equipment supply agreement, and in connection with a dispute over the capacity of the equipment supplied.  The interim findings did not specify monetary amounts for the parties’ respective claims, nor do we believe the amounts to be estimable, however we do not believe it to be material.  The final award of the arbitrator is expected in the latter part of the fourth quarter of 2007.



NOTE 11 NEW ACCOUNTING STANDARDS


In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements” (“SFAS No. 157”).  SFAS No. 157 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosure about fair value measurements.  This statement does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements.  SFAS 157 is effective for fiscal years beginning after November 15, 2007 and interim periods within those fiscal years.  We do not believe the adoption of SFAS No. 157 will have a material impact on our financial position, cash flows or results of operations.


In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities - Including an amendment of FASB Statement No. 115" (“SFAS No. 159”).  SFAS No. 159 allows measurement at fair value of eligible financial assets and liabilities that are not otherwise measured at fair value.  If the fair value option for an eligible item is elected, unrealized gains and losses for that item are reported in current earnings at each subsequent reporting date.  SFAS No. 159 also establishes presentation and disclosure requirements designed to draw comparisons between the different measurement attributes that we elect for similar types of assets and liabilities.  SFAS No. 159 is effective for fiscal years beginning after November 15, 2007.  



10




We are in the process of evaluating the application of the fair value option and the effect on our financial position and results of operations.



NOTE 12 – GEOGRAPHIC INFORMATION


Management has determined that we have two reportable segments, United States and Foreign Countries based on our consideration of the criteria detailed in SFAS No. 131, “Disclosures about Segments of an Enterprise and Related Information.”  Revenues are attributed to countries based on the location of customers.  Inter-company revenues recorded by the United States for work performed in Canada, which are immaterial, are eliminated prior to reporting United States revenues.  The same accounting principles and critical accounting policies are used in the preparation of the financial statements for both reporting segments.


Detailed information for our United States reporting segment is as follows:


In thousands

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2007

 

 

2006

 

 

2007

 

 

2006

Regulated medical waste management

   services

$

161,855

 

$

140,525

 

$

466,794

 

$

413,430

Regulated returns management services

 

22,258

 

 

15,854

 

 

62,568

 

 

42,925

Total revenue

 

184,113

 

 

156,379

 

 

529,362

 

 

456,355

Net interest expense

 

7,283

 

 

6,273

 

 

19,947

 

 

17,380

Income before income taxes

 

45,874

 

 

38,259

 

 

132,418

 

 

108,044

Income taxes

 

18,958

 

 

16,452

 

 

52,794

 

 

45,600

Net income

$

26,916

 

$

21,807

 

$

79,624

 

$

62,444

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

$

5,681

 

$

5,580

 

$

16,383

 

$

14,986


Detailed information for our Foreign Countries reporting segment is as follows:


In thousands

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2007

 

 

2006

 

 

2007

 

 

2006

Regulated medical waste management

   services

$

53,057

 

$

46,728

 

$

151,466

 

$

124,146

Property equipment and technology

   license sales

 

153

 

 

160

 

 

389

 

 

439

Total revenue

 

53,210

 

 

46,888

 

 

151,855

 

 

124,585

Net interest expense

 

1,274

 

 

1,047

 

 

3,648

 

 

2,592

Income before income taxes

 

7,182

 

 

6,876

 

 

20,764

 

 

16,916

Income taxes

 

1,203

 

 

1,151

 

 

6,108

 

 

3,135

Net income

$

5,979

 

$

5,725

 

$

14,656

 

$

13,781

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

$

2,127

 

$

1,521

 

$

6,271

 

$

5,123





11





ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


We were incorporated in 1989 and presently serve approximately 384,000 customers throughout the United States, United Kingdom, Mexico, Canada, Ireland, Argentina, and Puerto Rico.  In North America we have a fully integrated, national network.  Our network includes processing centers and transfer and collection sites.  We use this network to provide a broad range of services to our customers including regulated medical waste management services and regulated return management services.  Regulated medical waste management services include servicing a variety of customers to remove and process waste while regulated return management services are physical services provided to companies and individual businesses that assist with the handling of products that are being removed from the supply chain due to recalls and expiration.  These services also include advanced notification technology that is used to communicate specific instructions to the users of the product.  Our waste treatment technologies include autoclaving, incineration, chemical treatment and our proprietary electro-thermal-deactivation system.  In the United Kingdom and Ireland we have a fully integrated network, which includes processing/collection centers and transfer/collection sites.  In Argentina we own facilities that use incineration and autoclave treatments.  In addition, we have technology licensing agreements with companies located in Japan, Brazil, and South Africa.


Other than the adoption of FIN 48 (see Note 3 “Income Taxes”), there were no material changes in the Company’s critical accounting policies since the filing of its 2006 Form 10-K.  As discussed in the 2006 Form 10-K, the preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the amount of reported assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and revenues and expenses during the periods reported.  Actual results may differ from those estimates.



12






THREE MONTHS ENDED SEPTEMBER 30, 2007 COMPARED TO THREE MONTHS ENDED SEPTEMBER 30, 2006


The following summarizes the Company’s operations:


In thousands, except per share data

 

 

Three Months Ended September 30,

 

 

2007

 

 

2006

 

 

$

 

 

%

 

 

$

 

 

%

Revenues

$

237,323

 

 

100.0

 

$

203,267

 

 

100.0

Cost of revenues

 

130,509

 

 

55.0

 

 

112,744

 

 

55.5

Gross profit

 

106,814

 

 

45.0

 

 

90,523

 

 

44.5

Selling, general and administrative

   expenses

 

44,954

 

 

18.9

 

 

37,488

 

 

18.4

Income from operations

 

61,860

 

 

26.1

 

 

53,035

 

 

26.1

Net interest expense

 

8,557

 

 

3.6

 

 

7,320

 

 

3.6

Income tax expense

 

20,161

 

 

8.5

 

 

17,603

 

 

8.7

Net income

$

32,895

 

 

13.9

 

$

27,532

 

 

13.5

Earnings per share- diluted

$

0.37

 

 

 

 

$

0.30

 

 

 


Revenues.  Our revenues increased $34.0 million, or 16.8%, to $237.3 million in 2007 from $203.3 million in 2006.  Domestic revenues increased $27.7 million, or 17.7%, to $184.1 million from $156.4 million in 2006 as internal growth for domestic small account customers increased by approximately $9.4 million, or over 10%, primarily from an increase in Steri·Safe customers, and internal growth for large quantity customers increased by approximately $3.2 million, or 6.1%, primarily due to continued growth of Bio Systems™ accounts.  Internal growth for returns management was $5.6 million due to larger than expected one-time volumes, and domestic acquisitions less than one year old contributed approximately $9.5 million to the increase in domestic revenues.


International revenues increased $6.3 million to $53.2 million, or 13.5%, from $46.9 million in 2006.  Internal growth in the international segment contributed $4.7 million, or over 11% in increased revenues, before taking into consideration the effect of exchange rates, acquisitions, and divestitures.  The effect of exchange rates favorably impacted international revenues approximately $3.0 million while acquisitions less than one year old contributed another $2.8 million in international revenues.  The divestiture of selected STG plants in the first quarter of 2007 negatively impacted the comparison to 2006 by $4.2 million.


Cost of Revenues.  Our cost of revenues increased $17.8 million, or 15.8%, to $130.5 million during 2007 from $112.7 million during 2006.  Our domestic cost of revenues increased $12.3 million, or 15.1%, to $93.8 million from $81.5 million in 2006 as a result of costs related to a proportional increase in revenues from acquisitions and internal growth.  Our international cost of revenues increased $5.5 million to $36.7 million from $31.2 million in 2006 as a result of costs related to proportional increase in revenues from acquisitions and internal revenue growth.  Our gross margin percentage



13




increased to 45.0% during 2007 from 44.5% during 2006 due to an increase in the gross margins of our domestic business to 49.0% in 2007 from 47.9% in 2006 offsetting slightly lower gross margins in the international segment.  The increase in the gross margins of our domestic business was a result of increased efficiencies and higher margin service add-ons.  International gross margins were lower due to the divestiture of three plant locations and related higher third party disposal costs.  International gross margins are also lower than domestic gross margins because of the higher mix of large quantity generators in the international segment.  


Selling, General and Administrative Expenses.  Selling, general and administrative expenses, including acquisition related costs, increased to $45.0 million for the quarter ended September 30, 2007 from $37.5 million for the comparable quarter in 2006.  The increase was primarily due to costs associated with additional investment expense related to Steri·Safe and returns management, and legal costs associated with the arbitration hearings related to our dispute with SteriCorp.  As a percentage of revenue, these costs increased by 0.5% for the quarter ended September 30, 2007 compared to the same period in 2006.


Income from Operations.  Income from operations increased to $61.9 million for the quarter ended September 30, 2007 from $53.0 million for the comparable quarter in 2006, an increase of 16.6%, which is comparable to revenue increase of 16.8%.  Higher margins were offset by increased selling, general, and administrative expenses.  There were no one-time charges in either the quarter ended September 30, 2007 or the comparable period in 2006.


Net Interest Expense.  Net interest expense increased to $8.6 million during the quarter ended September 30, 2007 from $7.3 million during the comparable quarter in 2006 due to increased borrowings related to stock repurchases and acquisitions.  Interest rate fluctuations were minor and had no material effect.


Income Tax Expense.  Income tax expense increased to $20.2 million for the quarter ended September 30, 2007 from $17.6 million for the comparable quarter in 2006.  The increase was due to higher taxable income.  The effective tax rates for the quarters ended September 30, 2007 and 2006 were 38.0% and 39.0%, respectively.




14




NINE MONTHS ENDED SEPTEMBER 30, 2007 COMPARED TO NINE MONTHS ENDED SEPTEMBER 30, 2006


The following summarizes the Company’s operations:


In thousands, except per share data)

 

 

Nine Months Ended September 30,

 

 

2007

 

 

2006

 

 

$

 

 

%

 

 

$

 

 

%

Revenues

$

681,217

 

 

100.0

 

$

580,940

 

 

100.0

Cost of revenues

 

375,650

 

 

55.1

 

 

324,103

 

 

55.8

Gross profit

 

305,567

 

 

44.9

 

 

256,837

 

 

44.2

Selling, general and administrative

   expenses

 

128,669

 

 

18.9

 

 

108,795

 

 

18.7

Gain on sale of assets

 

(1,898)

 

 

(0.3)

 

 

--

 

 

--

Impairment of intangible assets

 

228

 

 

--

 

 

--

 

 

--

Impairment of fixed assets

 

1,261

 

 

0.2

 

 

300

 

 

0.1

Income from operations

 

177,307

 

 

26.0

 

 

147,742

 

 

25.4

Write-down of security investment

 

--

 

 

--

 

 

1,000

 

 

0.2

Net interest expense

 

23,595

 

 

3.4

 

 

19,972

 

 

3.4

Income tax expense

 

58,902

 

 

8.6

 

 

48,735

 

 

8.4

Net income

$

94,280

 

 

13.8

 

$

76,225

 

 

13.1

Earnings per share- diluted

$

1.05

 

 

 

 

$

0.84

 

 

 


Revenues.  Our revenues increased $100.3 million, or 17.3%, to $681.2 million in 2007 from $580.9 million in 2006.  Domestic revenues increased $73.0 million, or 16.0%, to $529.3 million from $456.3 million in 2006 as internal growth for domestic small account customers increased by approximately $26.4 million, or over 10.0%, due primarily to an increase in Steri·Safe customers, and internal growth for large quantity customers increased by approximately $9.2 million, or 5.9%, primarily due to continued growth of Bio Systems™ accounts.  Internal growth for returns management was $17.0 million, and acquisitions less than one year old contributed approximately $20.4 million to the increase in domestic revenues.


International revenues increased $27.3 million to $151.9 million, or 21.9% from $124.6 million in 2006.  Internal growth in the international segment contributed $11.6 million in increased revenues, before taking into consideration the effect of exchange rates, acquisitions, and divestitures.  The effect of exchange rates favorably impacted international revenues by approximately $7.3 million while acquisitions less than one year old contributed another $16.6 million in international revenues.  The divestiture of selected STG plants in the first quarter of 2007 negatively impacted the comparison to 2006 by $8.2 million.


Cost of Revenues.  Our cost of revenues increased $51.6 million, or 15.9%, to $375.7 million during 2007 from $324.1 million during 2006.  Our domestic cost of revenues increased $31.5 million, or 13.1%, to $271.6 million from $240.1 million in 2006 as a result of costs related to a proportional increase in revenues from acquisitions and internal growth.  Our international cost of revenues increased $20.1 million to $104.1



15




million from $84.0 million in 2006.  Our gross margin percentage increased to 44.9% during 2007 from 44.2% during 2006 due to an increase in the gross margins of our domestic business to 48.7% in 2007 from 47.4% in 2006 offsetting slightly lower gross margins in the international segment.  The increase in the gross margins of our domestic business was a result of increased efficiencies and higher margin service add-ons. International gross margins are lower than domestic gross margins because of the higher mix of lower-margin large quantity generators in the international segment.  


Selling, General and Administrative Expenses.  Selling, general and administrative expenses, including acquisition related costs, increased to $128.7 million for the nine months ended September 30, 2007 from $108.8 million for the comparable period in 2006.  The increase was primarily due to costs associated with additional revenues.  As a percentage of revenue, these costs increased by 0.2% for the nine months ended September 30, 2007 compared to the same period in 2006.


Income from Operations.  Income from operations increased to $177.3 million for the nine months ended September 30, 2007 from $147.7 million for the comparable period in 2006, an increase of 20.0% while revenues for the same periods increased 17.3%.  During 2007, we had permit and fixed asset write-offs offset by gains from the divestiture of selected STG facilities for a net effect of $0.4 million favorable to income from operations.  During the nine months ended September 30, 2006 we had a $0.3 million non-cash write-down of equipment.


Net Interest Expense.  Net interest expense increased to $23.6 million during the nine months ended September 30, 2007 from $20.0 million during the comparable period in 2006 due to increased borrowings related to stock repurchases and acquisitions.  Interest rate fluctuations had a negligible effect.


Income Tax Expense.  Income tax expense increased to $58.9 million for the nine months ended September 30, 2007 from $48.7 million for the comparable period in 2006.  The increase was due to higher taxable income.  The effective tax rates for the nine months ended September 30, 2007 and 2006 were 38.5% and 39.0%, respectively.



LIQUIDITY AND CAPITAL RESOURCES


On August 24, 2007, we amended and restated our $650.0 million senior unsecured revolving credit facility maturing in July 2011.  The credit facility was increased to $850.0 million and the maturity was extended to August 24, 2012.  At September 30, 2007, the margin for interest rates on borrowings under our new credit facility was 0.0% on base rate loans and 0.75% on LIBOR loans.  Our credit facility requires compliance with various financial, reporting and other covenants and restrictions, including a restriction on dividend payments.  At September 30, 2007, we were in compliance with all of our financial debt covenants.


As of September 30, 2007, we had $456.5 million of borrowings outstanding under our senior unsecured credit facility, which includes foreign currency borrowings of $16.0 million.  In addition, we had $69.8 million committed to outstanding letters of



16




credit.  The weighted average rate of interest on the unsecured revolving credit facility was 5.94% per annum.  At September 30, 2007 we had $105.1 million in other debt outstanding, which includes promissory notes issued in connection with acquisitions during 2004 through 2007 and some other foreign subsidiary bank debt, and $0.6 million in capital leases.


Working Capital.  At September 30, 2007, our working capital was $63.6 million compared to working capital of $76.6 million at December 31, 2006.  Of the decrease in working capital, $26.5 million related to the completion of the divestiture of selected STG plants that were classified as “Assets of disposal group held for sale” and “Liabilities of disposal group held for sale” and presented as current assets and current liabilities at December 31, 2006.  Working capital increased by $24.4 million due to higher accounts receivable and decreased $10.6 million due to higher accounts payable.  Cash was also used to pay down short-term debt which was $6.2 million less than at December 31, 2006.  


Net Cash Provided or Used.  Net cash provided by operating activities was $128.1 million during the nine months ended September 30, 2007 compared to $114.7 million for the comparable period in 2006.  The increase was primarily due to increased net income, accounts payable, and excess tax benefit related to stock compensation expensing, offset by decreased accrued liabilities.


Net cash used in investing activities for the nine months ended September 30, 2007 was $88.4 million compared to $170.8 million used in the comparable period in 2006.  The difference is due to approximately $64.0 million less paid for acquisitions and $26.5 million received from the divestiture of selected STG plants completed in February 2007, partially offset by $12.0 million in increased capital expenditures.


At September 30, 2007 we had approximately 9% of our treatment capacity in North America in incineration and approximately 91% in non-incineration technologies, such as autoclaving, and our proprietary patented ETD technology.  The implementation of our commitment to move away from incineration in North America may result in a write-down of the incineration equipment as and when we close incinerators that we are currently operating.  The net book value of our North American incinerators is approximately $7.4 million, or 0.5% of our total assets.  Our commitment to move away from incineration in North America is in the nature of a goal to be accomplished over an undetermined number of years.  Because of uncertainties relating, among other things, to customer education and acceptance and legal requirements to incinerate portions of the medical waste, we do not have a timetable for this transition or specific plans to close any of our existing incinerators.


Net cash used in financing activities was $44.1 million during the nine months ended September 30, 2007 compared to net cash provided of $55.3 million for the comparable period in 2006.  Approximately $69.1 million of this difference is the result of an increase in the repurchase of and cancellation of common stock over the prior year period, while another $18.4 million is related to paydown of long-term debt.




17




Guarantees:  We have guaranteed a loan to JPMorganChase Bank N.A. on behalf of Shiraishi-Sogyo Co. Ltd (“Shiraishi”).  Shiraishi is a customer in Japan that is expanding their medical waste management business and has a six month loan with a current balance of $4.2 million with JPMorganChase Bank N.A. that expires in November 2007.  The loan with JPMorganChase and our associated guarantee will be extended until May 2008.



ITEM 3.  QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK


We are subject to market risks arising from changes in interest rates.  Our potential additional interest expense over one year that would result from a hypothetical, instantaneous and unfavorable change of 100 basis points in the interest rate on all of our variable rate obligations would be approximately $4.8 million on a pre-tax basis.


We have exposure to currency exchange rate fluctuations between the U.S. dollar and U.K. pound sterling (“GBP”) related to an 11 million GBP inter-company loan to Stericycle International, Ltd., the parent company of White Rose Environmental.  We use cash flow hedge accounting treatment on our forward contracts.  Both the inter-company loan balance and the forward contracts are marked to market at the end of each reporting period and the impact on the balances is recorded on the balance sheet to other comprehensive income.


We have exposure to commodity pricing for gas and diesel fuel for our trucks and for the purchase of containers and boxes.  We do not hedge these items to manage the exposure.



ITEM 4.  CONTROLS AND PROCEDURES


Disclosure Controls and Procedures


Our management, with the participation of our President and Chief Executive Officer and our Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter covered by this Report.  On the basis of this evaluation, our President and Chief Executive Officer and our Chief Financial Officer each concluded that our disclosure controls and procedures were effective.


The term “disclosure controls and procedures” is defined in Rule 13a-14(e) of the Securities Exchange Act of 1934 as “controls and other procedures designed to ensure that information required to be disclosed by the issuer in the reports, files or submits under the Act is recorded, processed, summarized and reported, within the time periods specified in the [Securities and Exchange] Commission’s rules and forms.”  Our disclosure controls and procedures are designed to ensure that material information relating to us and our consolidated subsidiaries is accumulated and communicated to our management, including our President and Chief Executive Officer and our Chief



18




Financial Officer, as appropriate to allow timely decisions regarding our required disclosures.


Internal Control Over Financial Reporting


During the quarter ended September 30, 2007, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely materially to affect, our internal controls over financial reporting.


FROM TIME TO TIME WE ISSUE FORWARD-LOOKING STATEMENTS RELATING TO SUCH THINGS AS ANTICIPATED FINANCIAL PERFORMANCE, BUSINESS PROSPECTS, ACQUISITION ACTIVITIES AND SIMILAR MATTERS.


THESE FORWARD-LOOKING STATEMENTS MAY INVOLVE RISKS AND UNCERTAINTIES, SOME OF WHICH ARE BEYOND OUR CONTROL (FOR EXAMPLE, GENERAL ECONOMIC CONDITIONS).  OUR ACTUAL RESULTS COULD DIFFER SIGNIFICANTLY FROM THE RESULTS DESCRIBED IN THE FORWARD-LOOKING STATEMENTS.  FACTORS THAT COULD CAUSE SUCH DIFFERENCES INCLUDE DIFFICULTIES IN COMPLETING THE INTEGRATION OF ACQUIRED BUSINESSES, CHANGES IN GOVERNMENTAL REGULATION OF MEDICAL WASTE COLLECTION AND TREATMENT, AND INCREASES IN TRANSPORTATION AND OTHER OPERATING COSTS, AS WELL AS VARIOUS OTHER FACTORS.





19




PART II. – OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS


See Note 10, Legal Proceedings, in the Notes to the Condensed Consolidated Financial Statements (Item 1 of Part I).



ITEM 2.  CHANGES IN SECURITIES, USES OF PROCEEDS AND ISSUER PURCHASES OF EQUITY SECURITIES


In May 2002 our Board of Directors authorized the Company to repurchase up to 6,000,000 shares of our common stock, in the open market or through privately negotiated transactions, at times and in amounts in the Company’s discretion.

In February 2005, at a time when we had purchased a total of 2,956,860 shares, the Board authorized us to purchase an additional 2,956,860 shares.

In February 2007, at a time when we had purchased an additional 3,142,080 shares since the prior increase in authorization, the Board authorized us to purchase up to an additional 3,142,080 shares.

In May 2007, at a time when we had purchased an additional 923,142 shares since the prior increase in authorization, the Board authorized us to purchase up to an additional 923,142 shares, thereby again giving the Company the authority to purchase up to a total of 6,000,000 additional shares.  


The following table provides information about our purchases during the nine months ended September 30, 2007 of shares of our common stock.


Issuer Purchase of Equity Securities


 

Total Number of Share (or Unites) Purchased

 

 

Average Price Paid per Share (or Unit)

 

Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs

 

Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs

January 1- January 31, 2007

0

 

$

0

 

0

 

2,857,920

February 1- February 28, 2007

264,000

 

 

39.31

 

264,000

 

5,736,000

March 1- March 31, 2007

915,572

 

 

38.99

 

915,572

 

4,820,428

April 1- April 30, 2007

7,570

 

 

40.53

 

0

 

4,812,858

May 1- May 31, 2007

0

 

 

0

 

0

 

6,000,000

June 1- June 30, 2007

283,996

 

 

43.25

 

283,996

 

5,716,004

July 1- July 31, 2007

39,965

 

 

43.46

 

39,965

 

5,676,039

August 1- August 31, 2007

717,254

 

 

48.49

 

717,254

 

4,958,785

September 1- September 30, 2007

0

 

 

0

 

0

 

4,958,785




20




ITEM 6.  EXHIBITS


31.1

Rules 13a-14(a)/15d-14(a) Certification of Mark C. Miller, President and Chief Executive Officer


31.2

Rule 13a-14(a)/15d-14(a) Certification of Frank J.M. ten Brink, Executive Vice President and Chief Financial Officer


32

Section 1350 Certification of Mark C. Miller, President and Chief Executive Officer, and Frank J.M. ten Brink, Executive Vice President and Chief Financial Officer




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Dated: November 6, 2007

 

STERICYCLE, INC.

 

(Registrant)

 

By: 

/s/ Frank J.M. ten Brink

 

Frank J.M. ten Brink

 

Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)






21